Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study - Concepedia

Concepedia

Publication | Open Access

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

DOI Full Paper Access

124

Citations

19

References

2024

Year

Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Dejan Juric, Anthony W. Tolcher, Erika Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I. Spira,

Journal of Clinical Oncology

Abstract

In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.

References

	Year	Citations

Page 1